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	 p r e v i e w sOverlapping patterns of clinical behavior, 
tumor histology, and chromosomal altera-
tion among high-grade gliomas (HGGs) 
have been distilled into a central dogma 
that has governed much of our thinking 
about this disease over the last 20 years. 
For example, glioblastoma (GBM), which 
is the most aggressive form of HGG, 
is believed to arise through one of two 
mechanisms. GBMs that develop by pro-
gression from lower-grade tumors tend 
to occur in younger adults and frequently 
contain mutations in TP53. These so-
called secondary GBMs have been con-
trasted with primary GBMs that develop 
rapidly as de novo high-grade lesions in 
older patients. Primary GBMs are char-
acterized by a different set of genetic 
alterations that include the following: 
amplification of EGFR and HDM2, 
inactivating mutations in PTEN, and 
loss of all or a portion of chromo-
some 10. Unfortunately, this syn-
thesis of the various pathologic 
characteristics of HGG has failed to 
provide the level of understanding 
required to advance the treatment 
of this disease.
Microarray technologies have 
provided unbiased approaches to 
assess the validity of established 
paradigms of tumorigenesis. In this 
issue of Cancer Cell, Phillips et al. 
(2006) report the use of gene expres-
sion profiling to identify novel sub-
groups of HGG that are defined by 
distinct clinical and molecular char-
acteristics. This is not the first attempt to 
use gene expression profiling to improve 
understanding of gliomagenesis (Bredel 
et al., 2005; Freije et al., 2004; Godard 
et al., 2003; Liang et al., 2005; Mischel et 
al., 2003; Nigro et al., 2005; Rich et al., 
2005; Tso et al., 2006). However, while 
published studies have provided tran-
scriptional evidence that HGG comprises 
distinct subgroups, they have generally 
included too few numbers of tumors to 
reliably assess the clinical implications of 
these expression profiles. Phillips and col-
leagues adopted a supervised approach 
to guide their analyses. In this manner, 
they first divided 76 samples of HGG into 
those obtained from patients who experi-
enced either short or relatively long-term 
survival. They then used Spearman sta-
tistics to select the genes that were most 
significantly and differentially expressed 
between these two groups of tumors. 
Subsequent two-way cluster analysis 
segregated the 76 tumors into three dis-
tinct subclasses based on their prefer-
ential expression of genes characteristic 
of neural tissue (PN ), proliferating cells 
(Prolif ), or mesenchymal tissues (Mes ). 
The PN signature was significantly over-
represented among less aggressive forms 
of HGG, while the Prolif and Mes signa-
tures overlapped with poor risk disease 
(Figure 1). Importantly, similar analyses of 
two independent sets of HGG confirmed 
that tumors displaying the PN signature 
were associated with a more favorable 
prognosis. The PN signature also corre-
lated closely with established markers of 
better clinical outcome, including a young-
er age at diagnosis and grade III histology 
(Figure 1) (Buckner, 2003). This impact 
on clinical outcome was independent of 
tumor grade, since PN signature GBMs 
were associated with longer survival times 
than either Mes  or Prolif signature GBM.
These data confirm a growing lit-
erature indicating that gene expression 
profiling may predict the clinical outcome 
of HGG, even among patients with GBM 
(Freije et al., 2004; Liang et al., 2005; Nigro 
et al., 2005; Rich et al., 2005). However, 
more than prognostic markers, we need 
better treatments of HGG. The anticipated 
result of subclassifying tumors by expres-
sion profiling is that these immense data 
sets will take our understanding beyond 
current paradigms to unravel the patho-
genesis of the disease and pinpoint 
vulnerable areas for attack with novel 
therapies. The generation of genome-
wide expression profiles of a large 
number of well-characterized HGGs 
(>250) by Phillips and colleagues has 
provided us with an unprecedented 
resource with which to do this. As a 
first step in this process, the authors 
make some important initial obser-
vations from their data set. Of par-
ticular note, since the prognosis 
and gene expression profiles of 
HGGs are closely correlated, then 
the authors argue that these gene 
expression profiles may hold vital 
clues to the mechanisms that regu-
late glioma growth. In this regard, 
Phillips et al. liken the Mes, Prolif, 
and PN signatures to those of neural 
stem cells, transit-amplifying cells, 
and immature neurons, respective-
ly; suggesting that the aggressiveness of 
glioma growth may be governed by proc-
esses that regulate cell fate choices dur-
ing neurogenesis. These expression data 
complement recent evidence that gliomas 
may arise from stem cell-like cancer cells 
(Sanai et al., 2005). The authors go on 
to demonstrate that the gene expression 
signature of glioma cell lines correlates 
with the EGF/FGF-dependent proliferation 
of these cells (neurosphere formation) in 
culture. The authors interpret these find-
ings as an indication that the stem cell-like 
behavior of HGG might be predicted from 
tumor gene expression profiles. However, 
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The best efforts of clinicians and biologists battling high-grade glioma (HGG) have been overshadowed by two cruel facts: 
these tumors are essentially incurable and will kill most patients within months, and emergent knowledge of the genetic 
alterations in HGG has done nothing to ease this burden of suffering. In this issue of Cancer Cell, Phillips et al. report an 
extensive study of the gene expression profiles of a large cohort of HGG. Their data provide new clues to the origins of this 
disease and suggest potential targets for novel therapies.
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	 p r e v i e w sthe presented studies do not test the self-
renewal (serial transfer of neurospheres) 
or potency of glioma cells that are more 
rigorous analyses of the stem cell frac-
tion. Studies of glioma cells isolated from 
fresh samples of PN, Prolif, and Mes, sig-
nature tumors using more formal tests of 
stem cell function would better determine 
whether these expression profiles report 
the stem cell phenotype of HGG. These 
studies might also help to determine if the 
different expression subtypes of HGG are 
maintained by a common cell type, or rep-
resent more distinct forms of the disease 
that arise from transformed cells at differ-
ent stages along the neural differentiation 
pathway. Interestingly, the authors demon-
strate that some tumors display a switch 
in expression signature from PN to Mes 
following disease progression (Figure 1). 
Thus, expression subtypes of HGG may 
not be entirely distinct, but rather repre-
sent different stages or forms of a more 
common disease process. Comparison of 
the PN, Prolif, and Mes signatures to those 
of the available mouse models of glioma 
that have been derived from cells in dif-
ferent stages of differentiation (Bachoo et 
al., 2002) may provide further clues to the 
cellular origins of these HGG subtypes. 
Finally, the findings of Phillips et al. also 
have implications for the development 
of novel therapies of HGG. Perhaps the 
most significant of these is the demonstra-
tion that tumors with PN and Prolif/Mes 
signatures display evidence of activation 
of the NOTCH and AKT cell signal path-148 
Sphingosine-1-phosphate (S1P) is the 
simplest and most intriguing sphin-
golipid metabolite. Although S1P was 
initially considered as an intermedi-
ate in the ultimate degradation of all 
sphingolipids, its bewildering nature 
Targeting sphingosine
for cancer therapeutic
Sphingosine-1-phosphate (S1P) is a ple
cell invasion, vascular maturation, and a
Cancer Cell, Visentin et al. demonstrate th
significantly slows tumor progression an
suggest that S1P not only affects tumor
factors, and thus may be a bona fide canways, respectively. These cell signaling 
systems have been identified previously 
as potential targets for glioma treatment. 
Therefore, the efficiency of clinical trials 
that test inhibitors of NOTCH or AKT sig-
naling could be increased significantly by 
enrolling patients whose tumors display 
the PN or Prolif/Med expression signa-
ture, respectively.
The extensive expression profiling 
analysis by Phillips et al. represents an 
important step forward in our understand-
ing of the biology and treatment of HGG. 
Their integrated approach has provided 
important clues that may allow us ulti-
mately to identify the distinct molecular 
processes that result in the long-recog-
nized clinical and pathologic forms of 
these devastating diseases.
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receptors, designated S1P1–5, which 
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